Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Biperiden Hydrochloride (KL 373 Hydrochloride) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker and it is used for the adjunctive treatment of all forms of Parkinson's disease (postencephalitic, idiopathic, and arteriosclerotic)[1]. Target: M1 receptors Biperiden is an antiparkinsonian agent of the anticholinergic type. Biperiden has an atropine-like blocking effect on all peripheral structures which are parasympathetic-innervate and it also has a prominent central blocking effect on M1 receptors[2]. Biperiden (0.11 mg/kg), benactyzine (0.3 mg/kg),caramiphen (10 mg/kg), procyclidine (3 mg/kg), and trihexyphenidyl (0.12 mg/kg) separately and each in combination with physostigmine (0.1 mg/kg) is to make a comparative assessment of potential cognitive effects. The results showed that benactyzine, caramiphen, and trihexyphenidyl reduced rats' innate preference for novelty. Whereas biperiden and procyclidine did not [3]. Clinical indications: parkinsonism FDA Approved Date: Toxicity: Drowsiness; vertigo; headache; dizziness
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 2,690 | 35日内发货 | ||
50 mg | ¥ 11,500 | 35日内发货 |
产品描述 | Biperiden Hydrochloride (KL 373 Hydrochloride) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker and it is used for the adjunctive treatment of all forms of Parkinson's disease (postencephalitic, idiopathic, and arteriosclerotic)[1]. Target: M1 receptors Biperiden is an antiparkinsonian agent of the anticholinergic type. Biperiden has an atropine-like blocking effect on all peripheral structures which are parasympathetic-innervate and it also has a prominent central blocking effect on M1 receptors[2]. Biperiden (0.11 mg/kg), benactyzine (0.3 mg/kg),caramiphen (10 mg/kg), procyclidine (3 mg/kg), and trihexyphenidyl (0.12 mg/kg) separately and each in combination with physostigmine (0.1 mg/kg) is to make a comparative assessment of potential cognitive effects. The results showed that benactyzine, caramiphen, and trihexyphenidyl reduced rats' innate preference for novelty. Whereas biperiden and procyclidine did not [3]. Clinical indications: parkinsonism FDA Approved Date: Toxicity: Drowsiness; vertigo; headache; dizziness |
别名 | KL 373 (Hydrochloride), 盐酸比哌立登 |
分子量 | 347.92 |
分子式 | C21H30ClNO |
CAS No. | 1235-82-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 5 mg/mL (14.37 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O | 1 mM | 2.8742 mL | 14.3711 mL | 28.7422 mL | 71.8556 mL |
5 mM | 0.5748 mL | 2.8742 mL | 5.7484 mL | 14.3711 mL | |
10 mM | 0.2874 mL | 1.4371 mL | 2.8742 mL | 7.1856 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Biperiden Hydrochloride 1235-82-1 Others KL 373 KL-373 KL373 KL 373 (Hydrochloride) 盐酸比哌立登 Inhibitor inhibitor inhibit